|
Hana Biosciences, Inc. - Company Profile Snapshot
| Company Profile: |
Hana Biosciences, Inc. |
| Ticker: |
HNAB |
| Exchanges: |
OTC |
| 2008 Sales: |
n/a |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Service Organizations |
| Country: |
UNITED STATES |
| Employees: |
33 |
Business Description
Hana Biosciences, Inc.. The Group's principle activity is to acquire, develop and commercialize of innovative biopharmaceutical products to advance cancer care. It has four product candidates in various stages of development: Marqibo being developed for the treatment of adult acute lymphoblastic leukemia (ALL) and metastatic uveal melanoma. Menadione, a novel supportive care product candidate being developed for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors (EGFRI), a type of anti-cancer agent used in the treatment of certain cancers. Brakiva developed for the treatment of solid tumors including small cell lung cancer and ovarian cancer. Alocrest developed for the treatment of solid tumors such as non-small-cell lung cancer (NSCLC).
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
